Lenvatinib Plus Pembrolizumab Reinforces Long-Term Efficacy in Advanced RCC

Thomas Hutson, DO, PharmD, division chief of hematology/medical oncology and director of the UMC Cancer Center at Texas Tech University Health Science Center School of Medicine, discusses key takeaways from the phase 3 CLEAR trial (NCT02811861) evaluating lenvatinib (Lenvima) plus pembrolizumab (Keytruda) for the treatment of patients with advanced renal cell carcinoma (aRCC).

Thomas Hutson, DO, PharmD, division chief of hematology/medical oncology and director of the UMC Cancer Center at Texas Tech University Health Science Center School of Medicine, discusses key takeaways from the phase 3 CLEAR trial evaluating lenvatinib (Lenvima) plus pembrolizumab (Keytruda) for patients with advanced renal cell carcinoma (aRCC).

Presented at the 2025 Genitourinary Cancers Symposium, an abstract from the trial examined the impact of tumor burden at progression and changes in IMDC risk classification from baseline in patients treated with this combination. According to Hutson, these findings provide further insight into how disease characteristics evolve over time and their influence on treatment outcomes.

Hutson emphasizes that the updated results reinforce the strength of the original data, confirming the durability and efficacy of lenvatinib plus pembrolizumab in this setting. He highlights that both oncologists and patients should feel confident in this regimen as a leading option for aRCC, given its demonstrated long-term benefits.

Here, Hutson provides practical insights for community oncologists, offering guidance on integrating these findings into clinical practice to optimize patient outcomes in aRCC treatment.

Transcription:

0:10 | I think our updated results of lenvatinib plus pembrolizumab confirm the robustness of the original data. Doctors should feel very comfortable. Patients should feel very secure that this regimen is going to provide them the stated benefits. It stood the test of time, so they should feel very comfortable in choosing this as, if not the most active, one of the most active regimens for these patients.

REFERENCE:

Grunwald V, Keizman D, Bedke J, et al. Analyses on impact of tumor burden at progression and changes in IMDC from baseline in patients (pts) with advanced renal cell carcinoma (aRCC) treated with lenvatinib + pembrolizumab (L+P) in the phase 3 CLEAR trial. J Clin Oncol. 2025;43(suppl 5). Abstract 531.